Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) ...

Recce Pharma announces positive clinical data from phase II trial of RECCE 327 gel in acute bacterial skin & skin structure infections: Sydney Friday, February 21, 2025, 16:00 Hrs ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042 ...

The Phase II trial saw Recce 327 achieving all primary and secondary endpoints as the company looks to launch a Phase III trial.

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

The global biosurgery market is projected to grow at a CAGR of 5% from 2025 to 2030. This growth is driven by the increasing prevalence of chronic conditions necessitating surgical interventions, ...

Recce Pharmaceuticals Ltd has received positive findings from a Phase II clinical trial evaluating RECCE® 327 Topical Gel (R327G) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), ...

Available exclusively through Fox Pharma, the latest aesthetic innovation, VITARAN harnesses the power of trout DNA for a ...

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $25.00 price ...

Microba Life Sciences (ASX:MAP), which has technology for measuring the gut microbiome, has a strategic partnership deal with ...

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute ...